کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2019587 | 1542220 | 2013 | 9 صفحه PDF | دانلود رایگان |

The lipoxygenases (LOs) are principal enzymes involved in the oxidative metabolism of polyunsaturated fatty acids, including arachidonic acid. 12- and 15-LO and their lipid metabolites have been implicated in the development of insulin resistance and diabetes. Adipose tissue, and in particular visceral adipose tissue, plays a primary role in the development of the inflammation seen in these conditions. 12- and 15-LO and their lipid metabolites act as upstream regulators of many of the cytokines involved in the inflammatory response in adipose tissue. While the role that 12- and 15-LO play in chronically inflamed adipose tissue is becoming clearer, there are still many questions that remain unanswered regarding their activation, signaling pathways, and roles in healthy fat. 12- and 15-LO also generate products with anti-inflammatory properties that are under investigation. Therefore, 12- and 15-LO have the potential to be very important targets for therapeutics aimed at reducing insulin resistance and the comorbid conditions associated with obesity.
► 12- and 15-lipoxygenases are expressed in many tissues, including adipose tissue.
► 12- and 15-lipoxygenases can generate pro- and anti-inflammatory metabolites.
► 12-Lipoxygenase activity in adipocytes is required for adipocyte differentiation.
► 12- and 15-lipoxygenases in obesity promote the onset of metabolic dysfunction.
► Therapeutics against 12- and 15-lipoxygenases may treat metabolic dysfunction.
Journal: Prostaglandins & Other Lipid Mediators - Volumes 104–105, July–August 2013, Pages 84–92